Anti-chemokine therapy for inflammatory diseases

Int J Immunopathol Pharmacol. 2007 Jul-Sep;20(3):447-53. doi: 10.1177/039463200702000303.

Abstract

Chemokines are inflammatory proteins acting via G-protein coupled chemokine receptors that trigger different signaling pathways. Monocyte chemoattractant protein-1 (CCL2/MCP-1) and regulated on activation, normal T expressed and secreted (CCL5/RANTES) are the two major members of the CC chemokine beta subfamily. The roles of RANTES and MCP-1 are emerging in regulating the recruitment of inflammatory cells into tissue during inflammation. The inhibition of MCP-1 and RANTES with corresponding antibodies or other inhibitors may provide benefits in different clinical scenarios including cancer, inflammation, CNS disorders, parasitic disease, autoimmune and heart diseases. RANTES and MCP-1 may represent targets for diagnostic procedures and therapeutic intervention, and may be useful as a prognostic factor in the above diseases.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use
  • Chemokine CCL2 / antagonists & inhibitors
  • Chemokine CCL2 / immunology
  • Chemokine CCL5 / antagonists & inhibitors
  • Chemokine CCL5 / immunology
  • Chemokines / antagonists & inhibitors*
  • Chemokines / immunology
  • Humans
  • Inflammation / drug therapy*
  • Inflammation / immunology

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Chemokine CCL2
  • Chemokine CCL5
  • Chemokines